<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37153614</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1167055</StartPage><MedlinePgn>1167055</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1167055</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1167055</ELocationID><Abstract><AbstractText Label="BACKGROUND">To date a complete characterization of the components of the complement (C) pathways (CLassical, LEctin and ALternative) in patients with systemic lupus erythematosus (SLE) has not been performed. We aimed to assess the function of these three C cascades through functional assays and the measurement of individual C proteins. We then studied how they relate to clinical characteristics.</AbstractText><AbstractText Label="METHODS">New generation functional assays of the three pathways of the C system were assessed in 284 patients with SLE. Linear regression analysis was performed to study the relationship between the activity, severity, and damage of the disease and C system.</AbstractText><AbstractText Label="RESULTS">Lower values of the functional tests AL and LE were more frequent than those of the CL pathway. Clinical activity was not related to inferior values of C routes functional assays. The presence of increased DNA binding was negatively linked to all three C pathways and products, except for C1-inh and C3a which were positively related. Disease damage revealed a consistent positive, rather than a negative, relationship with pathways and C elements. Anti-ribosomes and anti-nucleosomes were the autoantibodies that showed a greater relationship with C activation, mainly due to the LE and CL pathways. Regarding antiphospholipid antibodies, the most related with C activation were IgG anti-&#x3b2;2GP, predominantly involving the AL pathway.</AbstractText><AbstractText Label="CONCLUSION">Not only the CL route, but also the AL and LE are related to SLE features. C expression patterns are linked to disease profiles. While accrual damage was associated with higher functional tests of C pathways, anti-DNA, anti-ribosomes and anti-nucleosomes antibodies, were the ones that showed a higher relationship with C activation, mainly due to the LE and CL pathways.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Garc&#xed;a-Gonz&#xe1;lez, G&#xf3;mez-Bernal, Quevedo-Abeledo, Fern&#xe1;ndez-Cladera, Gonz&#xe1;lez-Rivero, de Vera-Gonz&#xe1;lez, de la Rua-Figueroa, L&#xf3;pez-Mejias, D&#xed;az-Gonz&#xe1;lez, Gonz&#xe1;lez-Gay and Ferraz-Amaro.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garc&#xed;a-Gonz&#xe1;lez</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Bernal</LastName><ForeName>Fuensanta</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quevedo-Abeledo</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Doctor Negr&#xed;n, Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Cladera</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Rivero</LastName><ForeName>Agust&#xed;n F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vera-Gonz&#xe1;lez</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Rua-Figueroa</LastName><ForeName>I&#xf1;igo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Doctor Negr&#xed;n, Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Mejias</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqu&#xe9;s de Valdecilla, Instituto de Investigaci&#xf3;n sanitaria Marqu&#xe9;s de Valdecilla (IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-Gonz&#xe1;lez</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine. University of La Laguna (ULL), Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Gay</LastName><ForeName>Miguel &#xc1;</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Instituto de Investigaci&#xf3;n Sanitaria Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az (IIS-FJD), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Cantabria, Instituto de Investigaci&#xf3;n sanitaria Marqu&#xe9;s de Valdecilla (IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferraz-Amaro</LastName><ForeName>Iv&#xe1;n</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine. University of La Laguna (ULL), Tenerife, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">complement pathways</Keyword><Keyword MajorTopicYN="N">complement system</Keyword><Keyword MajorTopicYN="N">disease activity</Keyword><Keyword MajorTopicYN="N">disease damage</Keyword><Keyword MajorTopicYN="N">disease profiles</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Author IF-A received grants/research supports from Abbott, MSD, Janssen, and Roche, as well as consultation fees from company sponsored speakers bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, and MSD. Author MAG-G has received grants/research supports from AbbVie, MSD, Janssen, and Roche, as well as consultation fees/participation from company sponsored speakers bureaus tied to AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene, and MSD. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37153614</ArticleId><ArticleId IdType="pmc">PMC10160460</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1167055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol (2014) 32:433&#x2013;59. doi: 10.1146/annurev-immunol-032713-120154</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120154</ArticleId><ArticleId IdType="pubmed">24499275</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo ACL, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol (2016) 7:55. doi: 10.3389/fimmu.2016.00055</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00055</ArticleId><ArticleId IdType="pmc">PMC4764694</ArticleId><ArticleId IdType="pubmed">26941740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, et al. . Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum (2010) 62:837&#x2013;44. doi: 10.1002/art.27267</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27267</ArticleId><ArticleId IdType="pmc">PMC2917974</ArticleId><ArticleId IdType="pubmed">20187154</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein A, Alexander RV., Zack DJ. A review of complement activation in SLE. Curr Rheumatol Rep (2021) 23(3):16. doi: 10.1007/s11926-021-00984-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-00984-1</ArticleId><ArticleId IdType="pmc">PMC7875837</ArticleId><ArticleId IdType="pubmed">33569681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatol (1997) 40:1725. doi: 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowltz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol (2002) 29:288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. . The development and initial validation of the systemic lupus international collaborating Clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 39:363&#x2013;9. doi: 10.1002/art.1780390303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 24:S-99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">17083771</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz JD, Senegal J-L, Rivest C, Goulet J-R, Rothfield N. A simple severity of disease index for systemic lupus erythematosus. Lupus (1993) 2:119&#x2013;23. doi: 10.1177/096120339300200210</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339300200210</ArticleId><ArticleId IdType="pubmed">8330033</ArticleId></ArticleIdList></Reference><Reference><Citation>Troldborg A, Thiel S, Trendelenburg M, Friebus-Kardash J, Nehring J, Steffensen R, et al. . The lectin pathway of complement activation in patients with systemic lupus erythematosus. J Rheumatol (2018) 45:1136&#x2013;44. doi: 10.3899/jrheum.171033</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.171033</ArticleId><ArticleId IdType="pubmed">29907670</ArticleId></ArticleIdList></Reference><Reference><Citation>Palarasah Y, Nielsen C, Sprog&#xf8;e U, Christensen ML, Lillevang S, Madsen HO, et al. . Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system. Clin Exp Immunol (2011) 164:388&#x2013;95. doi: 10.1111/j.1365-2249.2011.04322.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2011.04322.x</ArticleId><ArticleId IdType="pmc">PMC3087935</ArticleId><ArticleId IdType="pubmed">21401574</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbore G, Kemper C, Kolev M. Intracellular complement - the complosome - in immune cell regulation. Mol Immunol (2017) 89:2&#x2013;9. doi: 10.1016/j.molimm.2017.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2017.05.012</ArticleId><ArticleId IdType="pmc">PMC7112704</ArticleId><ArticleId IdType="pubmed">28601357</ArticleId></ArticleIdList></Reference><Reference><Citation>K.Liszewski M, Atkinson JP. Complement regulators in human disease: lessons from modern genetics. J Intern Med (2015) 277:294&#x2013;305. doi: 10.1111/joim.12338</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12338</ArticleId><ArticleId IdType="pubmed">25495259</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, et al. . Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight (2018) 3(6):e99128. doi: 10.1172/jci.insight.99128</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.99128</ArticleId><ArticleId IdType="pmc">PMC5926944</ArticleId><ArticleId IdType="pubmed">29563339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmura K. Which is the best SLE activity index for clinical trials? Mod Rheumatol (2021) 31(1):20&#x2013;8. doi: 10.1080/14397595.2020.1775928</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2020.1775928</ArticleId><ArticleId IdType="pubmed">32475188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol (2004) 4(2):133&#x2013;42. doi: 10.1038/nri1269</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1269</ArticleId><ArticleId IdType="pubmed">15040586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HM, Wysoczynski M, Liu R, Shin DM, Kucia M, Botto M, et al. . Mobilization studies in complement-deficient mice reveal that optimal AMD3100 mobilization of hematopoietic stem cells depends on complement cascade activation by AMD3100-stimulated granulocytes. Leukemia (2010) 24:573&#x2013;82. doi: 10.1038/leu.2009.271</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2009.271</ArticleId><ArticleId IdType="pmc">PMC2838235</ArticleId><ArticleId IdType="pubmed">20033053</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastellos DC, DeAngelis RA, Lambris JD. Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Semin Immunol (2013) 25:29&#x2013;38. doi: 10.1016/j.smim.2013.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2013.04.002</ArticleId><ArticleId IdType="pmc">PMC3920450</ArticleId><ArticleId IdType="pubmed">23684626</ArticleId></ArticleIdList></Reference><Reference><Citation>Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol (2015) 6. doi: 10.3389/fimmu.2015.00262</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00262</ArticleId><ArticleId IdType="pmc">PMC4451739</ArticleId><ArticleId IdType="pubmed">26082779</ArticleId></ArticleIdList></Reference><Reference><Citation>Markiewski MM, Daugherity E, Karbowniczek M, Reese B. The role of complement in angiogenesis. antibodies. Antibodies (Basel) (2020) 9(4):67. doi: 10.3390/antib9040067</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib9040067</ArticleId><ArticleId IdType="pmc">PMC7709120</ArticleId><ArticleId IdType="pubmed">33271774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai YH, Deng J, Chen ZL, Mei H, Tang L, Luo SS, et al. . Brief report on the relation between complement C3a and anti dsDNA antibody in systemic lupus erythematosus. Sci Rep (2022) 12(1):7098. doi: 10.1038/s41598-022-10936-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-10936-z</ArticleId><ArticleId IdType="pmc">PMC9061720</ArticleId><ArticleId IdType="pubmed">35501405</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki T, Doi H, Tsuji H, Tabuchi Y, Hashimoto M, Kitagori K, et al. . Phenotypic landscape of systemic lupus erythematosus: An analysis of the Kyoto lupus cohort. Mod Rheumatol (2022) 32:571&#x2013;6. doi: 10.1093/mr/roab020</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mr/roab020</ArticleId><ArticleId IdType="pubmed">34894258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard EL, Pisetsky DS, Lipsky PE. Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE. Ann Rheum Dis 81:632&#x2013;43. doi: 10.1136/annrheumdis-2021-221662</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221662</ArticleId><ArticleId IdType="pubmed">35115332</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res (2016) 118(9):1392&#x2013;408. doi: 10.1161/CIRCRESAHA.116.306853</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.306853</ArticleId><ArticleId IdType="pubmed">27126649</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen KA, Seed P, Parmar K, Moore GW, Stuart-Smith SE, Hunt BJ. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost (2012) 107:423&#x2013;9. doi: 10.1160/TH11-08-0554</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH11-08-0554</ArticleId><ArticleId IdType="pubmed">22234447</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, et al. . Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis (2009) 68:1030&#x2013;5. doi: 10.1136/ard.2008.090670</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.090670</ArticleId><ArticleId IdType="pubmed">18625630</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin D, de Laat B, Devreese KMJ, Kelchtermans H. The clinical value of assays detecting antibodies against domain I of &#x3b2;2-glycoprotein I in the antiphospholipid syndrome. Autoimmun Rev (2018) 17:1210&#x2013;8. doi: 10.1016/j.autrev.2018.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.06.011</ArticleId><ArticleId IdType="pubmed">30316989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima T, Inoue D, Wajima T, Uchida T, Yamada M, Ohsawa I, et al. . Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis. Ren Fail (2022) 44(1):714&#x2013;23. doi:&#xa0;10.1080/0886022X20222068445</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X20222068445</ArticleId><ArticleId IdType="pmc">PMC9067964</ArticleId><ArticleId IdType="pubmed">35491890</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaskandan H, Kay Cheung C, Dormer J, et al. . Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis-associated nephritis. Nephron (2020) 144:453&#x2013;8. doi:&#xa0;10.1159/000508841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000508841</ArticleId><ArticleId IdType="pubmed">32721954</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AH, Pierce CO, De Salvo G, Griffiths H, Nelson M, Cree AJ, et al. . The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD. Eye (2021) 36:11. doi: 10.1038/s41433-021-01824-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-021-01824-3</ArticleId><ArticleId IdType="pmc">PMC9581945</ArticleId><ArticleId IdType="pubmed">34750590</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, et al. . Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U.S.A. (2020) 117:25018&#x2013;25. doi:&#xa0;10.1073/pnas.2010540117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010540117</ArticleId><ArticleId IdType="pmc">PMC7547220</ArticleId><ArticleId IdType="pubmed">32943538</ArticleId></ArticleIdList></Reference><Reference><Citation>Diatlov D, Bohorquez A, Jackson M, Cheong M, Kahr WHA, Kuo KHM, et al. . Pediatric sickle cell disease: A potential role for the complement system. Blood (2022) 140:2517&#x2013;8. doi: 10.1182/blood-2022-167696</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-167696</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>